The DOI matches its Crossref record.
In Vitro and in Vivo Study of Two Types of Long-Circulating Solid Lipid Nanoparticles Containing Paclitaxel.
Open accessAbstract
Paclitaxel (Taxol), a diterpenoid isolated from Taxus brevifolia, is effective against several murine tumors, and is one of the most exciting anticancer molecules currently available. Due to its low solubility in water, it is clinically administered with polyethoxylated castor oil (Cremophor EL), which causes serious side effects. Inclusion of paclitaxel in solid lipid nanoparticles (SLNs) has proved to be a good approach to eliminate the need for Cremophor EL and improve the drug's antitumor efficacy. This paper describes the development of two types of long-circulating SLNs as colloidal carriers for paclitaxel. SLNs are constituted mainly of bioacceptable and biodegradable lipids. In vitro release kinetics showed that the release was very slow, the release of paclitaxel from F68-SLN is linear, and the release of paclitaxel from Brij78-SLN followed the Weibull equation. Pharmacokinetics was evaluated in KM mice after injection of paclitaxel formulated in Cremophor EL or in Brij78-SLN and F68-SLN. Encapsulation of paclitaxel in both SLNs produced marked differences compared with the free drug pharmacokinetics. F68-SLN and Brij78-SLN are long-circulating (t 1/2 beta, 10.06 and 4.88 h, respectively) compared with paclitaxel injection (t 1/2 beta, 1.36 h).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Solid lipid nanoparticles for parenteral drug delivery
Wissing, S. A., Kayser, O., & Müller, R. H. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.12.002 · Cited by 1,495
Sapsford, K. E., Algar, W. R., Berti, L., Gemmill, K. B., Casey, B. J., Oh, E., Stewart, M. H., & Medintz, I. L. (2013) · Chemical Reviews · doi:10.1021/cr300143v · Cited by 1,423
Mohammadi-Samani, S., & Ghasemiyeh, P. (2018) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.235156 · Cited by 970
Recent Advances in Lipid Nanoparticle Formulations with Solid Matrix for Oral Drug Delivery
Das, S., & Chaudhury, A. (2011) · AAPS PharmSciTech · doi:10.1208/s12249-010-9563-0 · Cited by 838
Fonseca, C., Simões, S., & Gaspar, R. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00212-2 · Cited by 755
Arifin, D. Y., Lee, L. Y., & Wang, C.-H. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.007 · Cited by 674
Potential of solid lipid nanoparticles in brain targeting.
Kaur, I. P., Bhandari, R., Bhandari, S., & Kakkar, V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.018 · Cited by 615
Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles☆
WONG, H., BENDAYAN, R., RAUTH, A., LI, Y., & WU, X. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.008 · Cited by 578
Aptamer-functionalized PEG–PLGA nanoparticles for enhanced anti-glioma drug delivery
Guo, J., Gao, X., Su, L., Xia, H., Gu, G., Pang, Z., Jiang, X., Yao, L., Chen, J., & Chen, H. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.004 · Cited by 566
Paclitaxel Nano-Delivery Systems: A Comprehensive Review
Ma, P. (2013) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000164 · Cited by 559
Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles
Venkateswarlu, V., & Manjunath, K. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.01.005 · Cited by 558
Lipid nanoparticles for parenteral delivery of actives
Joshi, M. D., & Müller, R. H. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.003 · Cited by 433
Manjunath, K., & Venkateswarlu, V. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.06.006 · Cited by 380
Feng, S.-S., & Chien, S. (2003) · Chemical Engineering Science · doi:10.1016/s0009-2509(03)00234-3 · Cited by 364
Kinetic Analysis of Drug Release From Nanoparticles
Barzegar-Jalali, M. (2008) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3d59t · Cited by 343
Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB
Satapathy, M. K., Yen, T.-L., Jan, J.-S., Tang, R.-D., Wang, J.-Y., Taliyan, R., & Yang, C.-H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081183 · Cited by 318
Solid lipid nanoparticles: an oral bioavailability enhancer vehicle
Harde, H., Das, M., & Jain, S. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.604311 · Cited by 281
Das, S., Ng, W. K., Kanaujia, P., Kim, S., & Tan, R. B. H. (2011) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2011.07.036 · Cited by 274
Lai, F., Wissing, S. A., Müller, R. H., & Fadda, A. M. (2006) · AAPS PharmSciTech · doi:10.1208/pt070102 · Cited by 266
Nanocarrier for Poorly Water-Soluble Anticancer Drugs—Barriers of Translation and Solutions
Narvekar, M., Xue, H. Y., Eoh, J. Y., & Wong, H. L. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0107-x · Cited by 257
Bondì, M. L., Craparo, E. F., Giammona, G., & Drago, F. (2010) · Nanomedicine · doi:10.2217/nnm.09.67 · Cited by 175
Rostami, E., Kashanian, S., & Azandaryani, A. H. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3216-4 · Cited by 40
“Thus, they are capable to carry lipophilic or hydrophilic drug(s) for diagnostic and therapeutic purposes [8, 15, 20].”
Background
Metadata
- Authors
- CHEN, D.-B., YANG, T.-Z., LU, W.-L., & ZHANG, Q.
- Venue
- Chemical and Pharmaceutical Bulletin
- Publisher
- Pharmaceutical Society of Japan
- Published
- 2001
- Volume
- 49
- Issue
- 11
- Pages
- 1444-1447
- ISSN
- 0009-2363 (ISSN-L)
- 1347-5223
- OpenAlex
- W2166279159
- Cited by
- 243
- References
- 0
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.